Since then, ICIs targeting programmed cell death protein 1 (PD1 or CD279) and its ligand (PDL1 or CD274) have been approved for a varied and ever‐growing list of solid‐organ malignancies including melanoma, non‐small cell lung carcinoma (NSCLC), renal cell carcinoma (RCC), and urothelial carcinoma, amongst many others [3]. This evidence concerns the gene PDCD1 and urothelial carcinoma.